title: Plasma concentration of uroguanylin in patients on maintenance dialysis therapy.
abstract: BACKGROUND
  Uroguanylin, originally isolated from urine, is a new natriuretic peptide. Its plasma level is increased in association with renal impairment and fluid retention in patients with renal diseases.
  
  
  METHODS
  Uroguanylin concentrations were measured in patients on hemodialysis (HD, n = 76) and those on continuous ambulatory peritoneal dialysis (CAPD, n = 10) using a sensitive ra- dioimmunoassay for human uroguanylin.
  
  
  RESULTS
  Plasma concentrations of immunoreactive (ir)-uroguanylin in the patients on HD and CAPD (212.0 +/- 17.4 and 245.3 +/- 39.5 fmol/ml) were significantly higher than the value for the normal controls (5.0 +/- 0.3 fmol/ml). Plasma ir-uroguanylin levels before the start of regular HD were correlated with predialysis excess weight based on their dry weights (r = 0.33, p < 0.01) and with dialysis duration (r = 0.26, p < 0.05). The plasma levels in patients with HD, for whom high-flux membranes were used, were decreased at the end of regular HD as compared with the prior levels (p < 0.05), but not in those who underwent HD with conventional membranes.
  
  
  CONCLUSIONS
  These findings suggest that the plasma ir-uroguanylin level is related to the patient's volume status as well as renal impairment. Whether the accumulation of uroguanylin has a pathological effect has yet to be determined.
authors.affiliation: First Departments of Internal Medicine, Miyazaki Medical College, Miyazaki, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Fukae
authors.forename: H
authors.initials: H
authors.lastname: Kinoshita
authors.forename: S
authors.initials: S
authors.lastname: Fujimoto
authors.forename: M
authors.initials: M
authors.lastname: Nakazato
authors.forename: T
authors.initials: T
authors.lastname: Eto
mesh_terms: D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood; D001835:Body Weight; D005260:Female; D006801:Humans; D007118:Immunoassay; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D045265:Natriuretic Peptides; D010455:Peptides / Q000097:blood*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis
chemical_list: D008567:Membranes, Artificial; D045265:Natriuretic Peptides; D010455:Peptides; C084362:uroguanylin; D009320:Atrial Natriuretic Factor